CONGRESS PRESENTATIONS
EACS 2025
20th European AIDS Conference
Paris, France
October 15-18, 2025
-
ViiV-Sponsored Data
-
Cabotegravir Prevention
Boles J, et al.
Cabotegravir Injections Are More Acceptable Than Lenacapavir Injections Following a Single Dose: Results From CLARITY, a Randomized Crossover Study of Long-Acting Injectable Antiretrovirals
Metzner AA, et al.
Opportunities to Prevent Human Immunodeficiency Virus (HIV) Acquisition: Global Survey Results on Sexual Health Engagement in Newly Diagnosed People Living With HIV From the VOLITION Study
-
Cabotegravir Treatment
Ban JK, et al.
Real-World Utilization of Cabotegravir/Rilpivirine Long-Acting Injectable: An Observational Analysis of Adherence and Persistence using a Patient Support Program in Canada
Jonsson-Oldenbüttel C, et al.
The Power of Choice: Perspectives From Healthcare Providers on Early Switch to CAB+RPV LA After Rapid Suppression With DTG/3TC
Orkin C, et al.
Real-World Effectiveness and Tolerability of Cabotegravir + Rilpivirine Long-Acting in People Living with HIV-1: A Meta-Analysis of Real-World Evidence
Peters L, et al.
High Effectiveness and Rare Virologic Failure in Treatment-Experienced Individuals on Long-Acting Cabotegravir + Rilpivirine Therapy Across Europe: Insights from the EuroSIDA Study
-
Dolutegravir-based Regimens
Gökengin AD, et al.
TR-DOLA: Real-world data on the use of Dolutegravir (DTG) + Lamivudine (3TC) in treatment-experienced people living with HIV in TURKIYE
O’Brien P, et al.
PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine in Europe (PAIRED Europe): Primary Analysis
Papastamopoulos V, et al.
Real-world Effectiveness of DTG+3TC in PLHIV With Previous ART Experience but no Genotype Testing: The “AReTi” Study Results
Pérez-Elías MJ, et al.
The European REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV
Philibert P, et al.
CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine fixed dose combination in treatment-naïve adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France
-
Fostemsavir
-
Pipeline
Edwards AY, et al.
Population Pharmacokinetics, Antidrug Antibodies and Exposure-Response of VH3810109 (N6LS) in Virologically Suppressed Adults Living With HIV From the Phase 2b EMBRACE Study
Gartland M, et al.
Cutoff for Baseline Phenotypic Sensitivity to VH3810109 (N6LS) Did Not Impact Occurrence of Confirmed Virologic Failure in the Phase 2b EMBRACE Study
Griesel R, et al.
Safety and Tolerability of N6LS Administered Intravenously or Subcutaneously: Promising Results From Part 1 of the EMBRACE Study
Gutner CA, et al.
Evaluation of VH3810109 (N6LS) and Cabotegravir Long-Acting, Dual Modality, Injections for HIV Treatment: People With HIV and Staff Perspectives
-
Other Disease-Related Content
-
-
ViiV-Supported & Collaborative Data
-
Cabotegravir Prevention
Wang H, et al.
Chemsex, novel chemsex substances, associated risks for STIs, and an extended PrEP cascade among HIV-negative MSM, trans* individuals in 20 European countries: A latent class analysis
Wang H, et al.
Extended PrEP cascades and determinants of long-acting PrEP intention and unmet PrEP needs among transgender women, transgender men, and non-binary individuals in 20 European countries
Wang T, et al..
Intention to use long-acting injectable Pre-Exposure Prophylaxis among Belgian men who have sex with men – results of on online survey
-
Cabotegravir Treatment
Alain T, et al.
Reasons for switching to long-acting injectable antiretroviral therapy with cabotegravir/rilpivirine among adult people living with HIV: the real-life PANTER study
Alexa E, et al.
Real-world use of long-acting injectable cabotegravir and rilpivirine (LAI-CAB+RPV) in non-virally suppressed individuals: a systematic review of baseline characteristics, virological failure outcomes and discontinuations
Gagliardini R, et al.
Real-life switch to long-acting Cabotegravir/Rilpivirine ensures adequate drug levels without short-term impact on viral reservoir or inflammation: the Long-Icona Study
Pasin C, et al.
Discontinuations of long-acting injectable cabotegravir and rilpivirine in observational cohorts
Tanner C, et al.
Real-world implementation of long-acting injectable cabotegravir and rilpivirine: healthcare providers’ perspectives and experiences
Tenorio CH, et al.
Results at month 12 of CABO-CHANCE study: real-world-evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB+RPV LA) dosed every two months in viral suppressed people with HIV (PWH)
-
Dolutegravir-based Regimens
Avalos A, et al.
Real-World 5-Year Virologic Outcomes on PLHIV Initiated Efavirenz or Dolutegravir or Switched to Dolutegravir Containing Regimens in Botswana, 2012 -2025
Brites C, et al.
Adverse events and treatment discontinuation in a large, observational cohort of PLHIV starting Dolutegravir or non-Dolutegravir-based antiretroviral therapy (ART) in Brazil: The CODE cohort
Brites C, et al.
Subgroup Analysis of Dolutegravir/Lamivudine-in ART-Naïve Adults Living with HIV with CD4 counts below 200 cells/mL: Results from the DOLCE Study
De Lagarde M, et al.
Evolution of Proviral DNA M184V/I Over 96 Weeks Does Not Predict Virologic Failure of Dolutegravir/Lamivudine in the VOLVER Trial
Figueroa MI, et al.
Integrase Resistance Mutations in Treatment-Naive Persons with Advanced Immunodeficiency Initiating Dual Therapy with Dolutegravir and Lamivudine
Lins-Kusterer L, et al.
Changes in quality of life in people living with HIV switching to dolutegravir-based regimens, from stable or failing current antiretroviral regimens in the CODE cohort
Masia M, et al.
Virological non-inferiority and lower weight gain with DTG/3TC versus with BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, open-label, non-inferiority trial
Mchantaf G, et al.
HIV persistence in deep tissues on dolutegravir based antiretroviral therapy is not associated with the selection of drug resistance mutations to second generation INSTI (ANRS DOLUVOIR)
Vasylyev M, et al.
Switching to Dolutegravir/Lamivudine is Non-Inferior to Continuing Triple-Drug ART in Virologically Suppressed People With HIV: 2 year results of the DUALING Prospective Matched Nationwide Clinical Practice Study
-
Other Disease-Related Content
Allavena C, et al.
Four years frailty transitions in elderly adults living with HIV: Results from the SEPTAVIH Study
Castro DR, et al.
Ageing with HIV in France: When Patient Needs and Clinical Practice Diverge
Devonald M, et al.
"Ask Us" Europe, a community co-produced study: PLWH perspectives on treatment optimisation discussions with healthcare providers in 18 countries
Platte M, et al.
People with HIV at high cardiovascular risk were undertreated with statins independent of gender
-
